[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532079":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":18,"id":49,"slug":18,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":18,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":18,"enrollmentInfo":57,"targetDuration":18,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":18,"overallStatus":34,"whyStopped":18,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","Remind patients to test their immune status among 120-180 days post-transplantation. Physicians assessed the risk level of patients in the intervention group based on their immune status on days 91-180 using the CIRS.",[13],"Behavioral: Health monitoring and regular return follow-up reminders",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Only remind patients to test their immune status among 120-180 days post-transplantation.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BEHAVIORAL","Health monitoring and regular return follow-up reminders","Health monitoring \\& reminders for blood tests and follow-up visits until 1 year post-transplant",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Yahui Feng, MS","CONTACT","022-23909051","fengyahui@ihcams.ac.cn",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Institute of Hematology & Blood Diseases Hospital","RECRUITING","Tianjin","Tianjin Municipality","300020","China",{"type":40,"coordinates":41},"Point",[42,43],117.17667,39.14222,{"lat":43,"lon":42},[46],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},{"type":48,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100532079",false,"NCT06208137","Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.","Using the Composite Immune Risk Score to Assess and Modulate the Patient's Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation, a Prospective, Multicenter, Randomized Controlled Study.","Inclusion Criteria:\n\n* 1\\) Patients must be ≥ 16 years of age;\n* 2\\) Patients receiving haploidentical allo-HSCT;\n* 3\\) Patients have to sign an informed consent form before the start of the research procedure.\n\nExclusion Criteria:\n\n* 1\\) Tandem transplantation or multiple transplantations;\n* 2\\) Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements;\n* 3\\) Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.","ALL","16 Years",{"count":58,"type":59},456,"ESTIMATED","INTERVENTIONAL",[62],"NA","To assess the effectiveness of interventions including health monitoring and regular return follow-up reminders for patients with a high Composite Immune Risk Score.",[65],"Transplant-Related Disorder","2024-08-11",{"date":68,"type":69},"2024-08-13","ACTUAL",{"date":71,"type":69},"2024-02-29",{"date":73,"type":59},"2028-04-01",{"name":5,"class":6},1]